1-5 of 5
Emma Dean
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC

Natalie I. Vokes, Ana Galan Cobo, Margarita Fernandez-Chas, David Molkentine, Santiago Treviño, III, Vitaly Druker, Yu Qian, Sonia Patel, Stephanie Schmidt, Lingzhi Hong, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, J. Jack Lee, Marcelo V. Negrao, Don L. Gibbons, Ara Vaporciyan, Xiuning Le, Jia Wu, Jianjun Zhang, Una Rigney, Sonia Iyer, Emma Dean, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4958–4972.
https://doi.org/10.1158/1078-0432.CCR-23-1122
Published: 01 December 2023
View article titled, <em>ATM</em> Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
Open the PDF for <em>ATM</em> Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC in another window
Includes: Supplementary data
Journal Articles

C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

Stephanie L. Wethington, Payal D. Shah, Lainie Martin, Janos L. Tanyi, Nawar Latif, Mark Morgan, Drew A. Torigian, Diego Rodriguez, Simon A. Smith, Emma Dean, Susan M. Domchek, Ronny Drapkin, Ie-Ming Shih, Eric J. Brown, Wei-Ting Hwang, Deborah K. Armstrong, Stephanie Gaillard, Robert Giuntoli, Fiona Simpkins
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (15): 2800–2807.
https://doi.org/10.1158/1078-0432.CCR-22-2444
Published: 01 August 2023
View article titled, C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
Open the PDF for C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Timothy A. Yap, Matthew G. Krebs, Sophie Postel-Vinay, Anthony El-Khouiery, Jean-Charles Soria, Juanita Lopez, Alienor Berges, S.Y. Amy Cheung, Itziar Irurzun-Arana, Andrew Goldwin, Brunella Felicetti, Gemma N. Jones, Alan Lau, Paul Frewer, Andrew J. Pierce, Glen Clack, Christine Stephens, Simon A. Smith, Emma Dean, Simon J. Hollingsworth
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5213–5224.
https://doi.org/10.1158/1078-0432.CCR-21-1032
Published: 01 October 2021
View article titled, Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Open the PDF for Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study in another window
Journal Articles

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer

Seung Tae Kim, Simon A. Smith, Peter Mortimer, Arsene-Bienvenu Loembé, Heejin Cho, Kyoung-Mee Kim, Claire Smith, Sophie Willis, Itziar Irurzun-Arana, Alienor Berges, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Iwanka Kozarewa, Andrew J. Pierce, Emma Dean, Jeeyun Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4700–4709.
https://doi.org/10.1158/1078-0432.CCR-21-0251
Published: 01 September 2021
View article titled, Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
Open the PDF for Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer in another window
Includes: Supplementary data
Journal Articles

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014

Bristi Basu, Emma Dean, Martina Puglisi, Alastair Greystoke, Michael Ong, Wendy Burke, Maria Cavallin, Graham Bigley, Christopher Womack, Elizabeth A. Harrington, Stephen Green, Elisabeth Oelmann, Johann S. de Bono, Malcolm Ranson, Udai Banerji
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (15): 3412–3419.
https://doi.org/10.1158/1078-0432.CCR-14-2422
Published: 02 August 2015
View article titled, First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
Open the PDF for First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014 in another window
Includes: Supplementary data